

05 Feb 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: Amgen launches first US biosimilar to Humira; strong launches set to help BMS as it faces losses of exclusivity; Eisai preaches patience on Leqembi for Alzheimer's; 10 clinical trials to watch for this year; and Scrip Asks what 2023 holds in store for biopharma technological advances.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 3 February 2023, including: [Amgen, Inc.](#) launches first US biosimilar to Humira; strong launches set to help [Bristol Myers Squibb Company](#) as it faces losses of exclusivity; [Eisai Co., Ltd.](#) preaches patience on Leqembi for Alzheimer's; 10 clinical trials to watch for this year; and Scrip Asks what 2023 holds in store for biopharma technological advances.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[All Eyes On Amjevita, Amgen's Humira Biosimilar And Sole 2023 Product Launch](#)" - Scrip, 31 Jan, 2023.)

(Also see "[Strong Launches Will Help BMS Win The LOE Battle In 2023 And Beyond](#)" - Scrip, 30 Jan, 2023.)

(Also see "[Lessons Learnt From Aduhelm, Eisai Is Preaching Patience On Alzheimer's Drug Leqembi](#)"

- Scrip, 27 Jan, 2023.)

(Also see "[*10 Clinical Trials To Watch Out For In 2023*](#)" - Scrip, 26 Jan, 2023.)

(Also see "[*Scrip Asks...What Does 2023 Hold For Biopharma? Part 5: Technological Advances*](#)" - Scrip, 27 Jan, 2023.)

[Click here to explore this interactive content online](#) ✎